TAG
Treatment Action Group

Stop TB Partnership

TUBERCULOSIS RESEARCH
AND DEVELOPMENT:

2011 Report on Tuberculosis Research Funding Trends, 2005—2010 2nd Edition

COMPANION GRAPHS

TAG
Treatment Action Group

Stop TB Partnership

TUBERCULOSIS RESEARCH
AND DEVELOPMENT:

2011 Report on Tuberculosis Research Funding Trends, 2005—2010

2ND EDITION



MARCH 2012

TREATMENT ACTION GROUP

BY ELEONORA JIMÉNEZ-LEVI

Total TB R&D Funding: 2005-2010



2010 TB R&D investments witnessed a 76% increase over 2005 levels but only 2% growth since 2009.

Total TB R&D Funding: by Donor Sector: 2010
Total: $630,446,462



Total TB R&D Funding by Donor Sector: 2005-2010



	Public*	Philanthropy	Private	Multilateral
2005	$234,503,645	$78,178,708	$43,095,353	$1,648,083
2006	$246,862,858	$116,289,274	$53,138,347	$1,534,259
2007	$272,404,317	$132,326,981	$69,387,383	N/A
2008	$264,944,215	$154,513,987	$72,018,715	N/A
2009	$395,326,911	$123,383,703	$99,973,537	$525,385
2010	$376,189,816	$123,974,117	$124,249,938	$6,022,590

*** Includes funding from International Development Agencies**

Investments in TB R&D by Research Category: 2005-2010



	Drugs	Basic Science	Vaccines	Infrastructure Unspecified	Diagnostics	Operational Research
2005	$114,862,738	$81,892,167	$68,351,530	$40,741,527	$19,408,124	$32,170,084
2006	$144,336,532	$91,643,009	$76,555,111	$43,205,600	$31,890,329	$30,194,127
2007	$170,233,497	$113,325,202	$73,225,383	$40,734,199	$42,435,113	$33,967,288
2008	$174,178,052	$98,728,019	$109,337,224	$25,032,930	$49,788,950	$34,411,742
2009	$191,483,304	$172,447,841	$110,133,485	$56,686,918	$38,921,229	$49,536,760
2010	$230,540,443	$129,008,413	$78,446,298	$83,145,063	$48,410,889	$60,895,355

Total TB Investments by Research Category: 2010
Total: $630,446,462



Basic Science: $129,008,413



TB Diagnostics: $48,410,889



TB Drugs: $230,540,443



TB Vaccines: $78,446,298



Operational Research: $60,895,355



Annual Global Plan Research Funding Targets vs. 2010 Investments

TB R&D PDPs and Research Consortia: 2005-2010



	Aeras	CREATE	FIND	TB Alliance	TBVAC	TDR	TBVI	OETC	EDCTP
2005	$18,580,139	$10,000,000	$6,778,239	$7,874,983	$5,445,450	N/A	N/A	N/A	N/A
2006	$25,923,809	$8,298,826	$5,492,942	$14,808,362	$4,451,895	$2,995,748	N/A	N/A	$580,039
2007	$37,704,051	$12,375,000	$1,145,409	$22,624,182	$6,091,335	$453,382	N/A	N/A	$805,625
2008	$48,679,266	$18,493,585	$14,177,202	$26,885,734	$3,944,425	$3,817,352	$339,741	$1,196,000	$1,416,064
2009	$50,792,515	$12,786,985	$9,975,320	$35,643,490	$5,634,040	$4,243,264	$841,333	$2,851,000	$10,343,479
2010	$41,572,980	$5,410,545	$8,212,896	$37,538,794	Concluded	$3,900,000	$3,700,914	$7,142,159	$9,081,799

Top Ten Funders in TB R&D in 2010

Rank	Funder	Total	Basic Science	Applied/ unspecified	Diagnostics	Drugs	Vaccines	Operational Research
1	US NIAID, NIH	$158,030,390	$56,087,492	$23,199,096	$15,827,177	$41,871,408	$12,903,672	$8,141,545
2	Bill & Melinda Gates Foundation	$115,259,533	$4,426,910	$35,489,161	$14,728,436	$20,707,825	$30,449,862	$9,457,339
3	Otsuka	$63,648,753	$0	$0	$0	$63,648,753	$0	$0
4	US Other NIH Institutes & Centers	$52,363,574	$16,231,201	$12,512,524	$1,664,190	$5,290,414	$1,829,905	$14,835,340
5	European Commission	$25,866,089	$4,469,373	$2,011,431	$411,115	$7,670,696	$10,574,487	$728,987
6	Company X	$20,645,794	$0	$0	$0	$20,645,794	$0	$0
7	US CDC	$19,865,178	$0	$4,039,629	$1,706,565	$10,968,228	$0	$3,150,756
8	USAID	$19,791,027	$0	$500,000	$1,802,000	$7,046,029	$0	$10,442,998
9	UK DfID	$16,912,287	$0	$44,996	$749,930	$10,775,450	$3,646,920	$1,694,991
10	AstraZeneca	$14,023,381	$0	$0	$0	$14,023,381	$0	$0

Conclusions

• In 2010, 74 funders invested $630.4 million on TB R&D, a 76% increase over 2005 levels but only 2% growth since 2009.

• The top 10 TB R&D donors spent $506.4 million in 2010, or 80% of the total global spend.

• PDPs and research consortia spent $116.6 in TB R&D in 2010, 12% less than 2009 spending levels.

• Across the five *Global Plan* research areas, operational research came the closest to reaching its annual target at 76% and TB diagnostics was the farthest—only 14% of the annual target.

Conclusions

- The US NIAID continued to be the leading TB R&D funder in 2010, investing $158 million.
    - NIAID was the leading funder in basic science and TB diagnostics; and
    - the second leading funder of TB drugs and vaccines.

- Overall, the NIH spent $224 million in 2010—36% of the R&D total. American Recovery and Reinvestment Act stimulus funding provided $35.3 million, or 16%, of NIH's TB budget.

Recommendations

- To protect the scientific progress in TB R&D and close the $1.37 billion funding gap, donors must remain committed to funding TB R&D and emerging economies must scale-up their investments.

- To invest more in basic science, particularly biomarker discovery work.

- To support efficient and open access sample banks that house important samples to facilitate biomarker identification and validation.

- To increase funding to enhance clinical trial capacity for all stages of TB drug and vaccine trials.

- To clarify regulatory approval requirements for new TB drugs and regimens.